SEARCH

SEARCH BY CITATION

References

  • 1
    Buell JF, Gross TG, Woodle ES. Malignancy after transplantation. Transplantation 2005; 80(2 Suppl): S254S264. Epub 2005/10/28.
  • 2
    Hatton O, Lambert SL, Philips LK, et al. Syk-induced PI3K/AKT activation in Epstein−Barr virus (EBV+) post-transplant lympoproliferative disorder. Am J Transplant 2013; 13: 883890.
  • 3
    Wander SA, Hennessy BT, Slingerland JM. Next-generation mTOR inhibitors in clinical oncology: How pathway complexity informs therapeutic strategy. J Clin Invest 2011; 121: 12311241. Epub 2011/04/15.
  • 4
    Zaytseva YY, Valentino JD, Gulhati P, Evers BM. mTOR inhibitors in cancer therapy. Cancer Lett 2012; 319: 17. Epub 2012/01/21.
  • 5
    Nepomuceno RR, Balatoni CE, Natkunam Y, Snow AL, Krams SM, Martinez OM. Rapamycin inhibits the interleukin 10 signal transduction pathway and the growth of Epstein−Barr virus B-cell lymphomas. Cancer Res 2003; 63: 44724480. Epub 2003/08/09.
  • 6
    Krams SM, Martinez OM. Epstein−Barr virus, rapamycin, and host immune responses. Curr Opin Organ Transplant 2008; 13: 563568. Epub 2008/12/09.
  • 7
    Geissler EK, Schlitt HJ, Thomas G. mTOR, cancer and transplantation. Am J Transplant 2008; 8: 22122218. Epub 2008/09/13.
  • 8
    Luan FL, Ding R, Sharma VK, Chon WJ, Lagman M, Suthanthiran M. Rapamycin is an effective inhibitor of human renal cancer metastasis. Kidney Int 2003; 63: 917926.
  • 9
    Mathew T, Kreis H, Friend P. Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: Results from five multicenter studies. Clin Transplant 2004; 18: 446449.
  • 10
    Kahan BD, Camardo JS. Rapamycin: Clinical results and future opportunities. Transplantation 2001; 72: 11811193.
  • 11
    Campistol JM, Eris J, Oberbauer R, et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol 2006; 17: 581589.
  • 12
    Kauffman HM, Cherikh WS, Cheng Y, Hanto DW, Kahan BD. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 2005; 80: 883889. Epub 2005/10/27.
  • 13
    Piselli P, Serraino D, Segoloni GP, et al. Risk of de novo cancers after transplantation: Results from a cohort of 7217 kidney transplant recipients, Italy 1997−2009. Eur J Cancer 2013; 49: 336344. Epub 2012/10/16.
  • 14
    Kirk AD, Cherikh WS, Ring M, et al. Dissociation of depletional induction and posttransplant lymphoproliferative disease in kidney recipients treated with alemtuzumab. Am J Transplant 2007; 7: 26192625.
  • 15
    McDonald RA, Smith JM, Ho M, et al. Incidence of PTLD in pediatric renal transplant recipients receiving basiliximab, calcineurin inhibitor, sirolimus and steroids. Am J Transplant 2008; 8: 984989.
  • 16
    Caillard S, Dharnidharka V, Agodoa L, Bohen E, Abbott K. Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression. Transplantation 2005; 80: 12331243.
  • 17
    Iaria G, Anselmo A, De Luca L, et al. Conversion to rapamycin immunosuppression for malignancy after kidney transplantation: Case reports. Transplant Proc 2007; 39: 20362037.
  • 18
    Cullis B, D'Souza R, McCullagh P, et al. Sirolimus-induced remission of posttransplantation lymphoproliferative disorder. Am J Kidney Dis 2006; 47: e67e72.
  • 19
    Boratynska M, Watorek E, Smolska D, Patrzalek D, Klinger M. Anticancer effect of sirolimus in renal allograft recipients with de novo malignancies. Transplant Proc 2007; 39: 27362739.
  • 20
    Gomez-Camarero J, Salcedo M, Rincon D, et al. Use of everolimus as a rescue immunosuppressive therapy in liver transplant patients with neoplasms. Transplantation 2007; 84: 786791. Epub 2007/09/26.
  • 21
    Pascual J. Post-transplant lymphoproliferative disorder—The potential of proliferation signal inhibitors. Nephrol Dial Transplant 2007; 22 (Suppl 1): i27i35.
  • 22
    Manuelli M, De Luca L, Iaria G, et al. Conversion to rapamycin immunosuppression for malignancy after kidney transplantation. Transplant Proc 2010; 42: 13141316. Epub 2010/06/11.
  • 23
    Bishop GA, Hostager BS. Signaling by CD40 and its mimics in B cell activation. Immunol Res 2001; 24: 97109. Epub 2001/10/12.
  • 24
    Mancao C, Hammerschmidt W. Epstein−Barr virus latent membrane protein 2A is a B-cell receptor mimic and essential for B-cell survival. Blood 2007; 110: 37153721. Epub 2007/08/08.
  • 25
    Hatton O, Phillips LK, Vaysberg M, Hurwich J, Krams SM, Martinez OM. Syk activation of phosphatidylinositol 3-kinase/Akt prevents HtrA2-dependent loss of X-linked inhibitor of apoptosis protein (XIAP) to promote survival of Epstein−Barr virus+ (EBV+) B cell lymphomas. J Biol Chem 2011; 286: 3736837378. Epub 2011/09/13.
  • 26
    Lambert SL, Martinez OM. Latent membrane protein 1 of EBV activates phosphatidylinositol 3-kinase to induce production of IL-10. J Immunol 2007; 179: 82258234.
  • 27
    Hatton O, Lambert SL, Krams SM, Martinez OM. Src kinase and Syk activation initiate PI3K signaling by a chimeric latent membrane protein 1 in Epstein−Barr virus (EBV)+ B cell lymphomas. PLoS ONE 2012; 7: e42610. Epub 2012/08/11.
  • 28
    De Luca A, Maiello MR, D'Alessio A, Pergameno M, Normanno N. The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: Role in cancer pathogenesis and implications for therapeutic approaches. Expert Opin Therapeutic Targets 2012; 16 (Suppl 2): S17S27. Epub 2012/03/27.
  • 29
    Klippel A, Kavanaugh WM, Pot D, Williams LT. A specific product of phosphatidylinositol 3-kinase directly activates the protein kinase Akt through its pleckstrin homology domain. Mol Cell Biol 1997; 17: 338344. Epub 1997/01/01.
  • 30
    Vanhaesebroeck B, Welham MJ, Kotani K, et al. P110delta, a novel phosphoinositide 3-kinase in leukocytes. Proc Natl Acad Sci USA 1997; 94: 43304335. Epub 1997/04/29.
  • 31
    Tzenaki N, Andreou M, Stratigi K, et al. High levels of p110delta PI3K expression in solid tumor cells suppress PTEN activity, generating cellular sensitivity to p110delta inhibitors through PTEN activation. FASEB J 2012; 26: 24982508. Epub 2012/03/07.
  • 32
    Gibbons JJ, Abraham RT. Yu K. Mammalian target of rapamycin: Discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth. Sem Oncol 2009; 36 (Suppl 3): S3S17. Epub 2010/01/09.
  • 33
    O'Reilly KE, Rojo F, She QB, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006; 66: 15001508. Epub 2006/02/03.
  • 34
    Beatty PR, Krams SM, Martinez OM. Involvement of IL-10 in the autonomous growth of EBV-transformed B cell lines. J Immunol 1997; 158: 40454051.
  • 35
    Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell 2012; 149: 274293. Epub 2012/04/17.
  • 36
    Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005; 307: 10981101. Epub 2005/02/19.
  • 37
    Majewski M, Korecka M, Kossev P, et al. The immunosuppressive macrolide RAD inhibits growth of human Epstein−Barr virus-transformed B lymphocytes in vitro and in vivo: A potential approach to prevention and treatment of posttransplant lymphoproliferative disorders. Proc Natl Acad Sci USA 2000; 97: 42854290.
  • 38
    Bi L, Okabe I, Bernard DJ, Wynshaw-Boris A, Nussbaum RL. Proliferative defect and embryonic lethality in mice homozygous for a deletion in the p110alpha subunit of phosphoinositide 3-kinase. J Biol Chem 1999; 274: 1096310968. Epub 1999/04/10.
  • 39
    Bi L, Okabe I, Bernard DJ, Nussbaum RL. Early embryonic lethality in mice deficient in the p110beta catalytic subunit of PI 3-kinase. Mammalian Genome 2002; 13: 169172. Epub 2002/03/29.
  • 40
    Foukas LC, Claret M, Pearce W, et al. Critical role for the p110alpha phosphoinositide-3-OH kinase in growth and metabolic regulation. Nature 2006; 441: 366370. Epub 2006/04/21.
  • 41
    Clayton E, Bardi G, Bell SE, et al. A crucial role for the p110delta subunit of phosphatidylinositol 3-kinase in B cell development and activation. J Exp Med 2002; 196: 753763. Epub 2002/09/18.
  • 42
    Jou ST, Carpino N, Takahashi Y, et al. Essential, nonredundant role for the phosphoinositide 3-kinase p110delta in signaling by the B-cell receptor complex. Mol Cell Biol 2002; 22: 85808591. Epub 2002/11/26.
  • 43
    Puri KD, Gold MR. Selective inhibitors of phosphoinositide 3-kinase delta: Modulators of B-cell function with potential for treating autoimmune inflammatory diseases and B-cell malignancies. Front Immunol 2012; 3: 256. Epub 2012/09/01.
  • 44
    Shair KH, Schnegg CI, Raab-Traub N. EBV latent membrane protein 1 effects on plakoglobin, cell growth, and migration. Cancer Res 2008; 68: 69977005. Epub 2008/09/02.
  • 45
    Herman SE, Gordon AL, Wagner AJ, et al. Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood 2010; 116: 20782088. Epub 2010/06/05.
  • 46
    Meadows SA, Vega F, Kashishian A, et al. PI3Kdelta inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma. Blood 2012; 119: 18971900. Epub 2012/01/03.
  • 47
    Ikeda H, Hideshima T, Fulciniti M, et al. PI3K/p110{delta} is a novel therapeutic target in multiple myeloma. Blood 2010; 116: 14601468. Epub 2010/05/28.
  • 48
    Macias-Perez IM, Flinn IW. GS-1101: A delta-specific PI3K inhibitor in chronic lymphocytic leukemia. Curr Hematol Malignancy Rep 2012; Epub 2012/11/02.